Lantheus Holdings, Inc. is a global pharmaceutical company dedicated to the development, manufacturing, and commercialization of advanced diagnostic and therapeutic agents. Their ...
Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer
Est. EPS $1.26 · Revenue $360.41M · 5 analysts
Est. EPS $1.32 · Revenue $371.14M · 4 analysts
Est. EPS $5.37 · Revenue $1.48B · 4 analysts
Est. EPS $1.45 · Revenue $391.98M · 1 analysts
| Metric | Latest | YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength. | QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes. |
|---|---|---|---|
| RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three). | $1.5B | +0.5% | +2.9% |
| Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day. | $233.6M | -25.2% | -36.6% |
| Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials. | +61.1% | -5.2% | +1.8% |
| Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on). | +20.2% | -32.3% | +19.8% |
| Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales. | +15.2% | -25.6% | -38.4% |
| Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock. | $354.1M | -28.2% | +73.7% |
| FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine. | +23.0% | -28.6% | +68.9% |
| Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe. | 56.8% | -0.2% | -7.7% |
| Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking. | 2.70x | -51.1% | +8.2% |
| Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground. | $2.2B | +12.5% | +2.9% |
| Metric | Annual (A vs E) | Annual Surprise | Quarter (A vs E) | Quarter Surprise |
|---|---|---|---|---|
| EPS Surprise | 3.41 vs 5.57 | -38.8% | 1.11 vs 1.26 | -11.8% |
| Revenue Surprise | $1.5B vs $1.5B | +2.6% | $388.2M vs $360.4M | +7.7% |
| Date | Executive | Title | Security | Side | Shares | Price |
|---|---|---|---|---|---|---|
| Aug 31, 2026 | Marshall Robert J. Jr. | officer: CFO and Treasurer | Common Stock | D | 721 | $100.96 |
| Aug 17, 2026 | Dinkelborg Ludger | officer: See Remarks | Common Stock | D | 2,536 | $100.91 |
| Aug 17, 2026 | Brown Kimberly | officer: Chief Accounting Officer | Common Stock | D | 463 | $100.91 |
| May 14, 2026 | McHugh Julie | director | Common Stock | A | 4,137 | — |
| May 14, 2026 | Morrow Phuong Khanh | director | Common Stock | A | 4,137 | — |
Operator: Good morning. Welcome to Lantheus' First Quarter 2026 Conference Call. This call is being recorded, and a replay will be available in the Investors section of the company's website approximately 2 hours after the completion of the call and will be archived for at least 30 days. I'll now turn the call over to Mark Kinarney, Vice President of Investor Relations. Mark? Mark Kinarney: Thank you. Good morning. With me today are Mary Heino, our CEO and Executive Chairperson; Amanda Morgan, our Chief Commercial Officer; and Bob Marshall, our CFO. We will begin with prepared remarks and then take your questions. This morning, we issued a press release, which was furnished to the SEC under Form 8-K reporting our first quarter 2026 results. The release and today's slide presentation are available on the Investors section of our website. Any comments could include forward-looking statements. Actual results may differ materially from these statements due to a variety of risks and uncertainties, which are detailed in our SEC filings. Discussions will also include certain non-GAAP financial measures. Reconciliation of these measures to the most directly comparable GAAP financial measures is included in the Investors section of our website. I will now turn the call over to Mary Anne. Mary Heino: Thank you, Mark, and good morning, everyone. We had a strong start to the year with solid performance across PYLARIFY, NEURACEQ and DEFINITY. These results reflect our ongoing commitment to focus and discipline across the organization. As we said last quarter, 2026 is a year of commercial execution and regulatory milestones. We're making deliberate choices about where we focus our commercial efforts and deploying capital so we're positioned to deliver solid results in 2026 and accelerate growth in 2027. Our corporate focus is centered on radio diagnostics and our priorities for 2026 are clear. First, maintain our market leadership in PSMA PET while preparing for a seamless transition to PYLARIFY TRUVU, our newly approved PSMA PET formulation beginning in the fourth quarter. Second, continue to build momentum for NEURACEQ through deeper penetration within existing accounts, leveraging the breadth of the Lantheus portfolio to unlock incremental growth opportunities and expanding our manufacturing footprint, increasing supply availability. Third, advance our late-stage clinical portfolio through key regulatory milestones and ensure launch readiness aligned with coding, coverage, payment, customer preparedness and market opportunity. And finally, allocate capital with discipline, prioritizing radio diagnostics while evaluating value-maximizing alternatives for our radiotherapeutic assets. In addition to effective commercial execution, we advanced several key programs during the quarter that support our long-term growth strategy. On March 6, the FDA approved PYLARIFY TRUVU, our new PSMA PET imaging agent. PYLARIFY TRUVU offers the same proven diagnostic properties …
| Name | Title | Compensation | Gender | Year Born | Status |
|---|---|---|---|---|---|
Ludger Dinkelborg | Head of Research & Development | USD 13,659,644 | — | 1963 | Active |
Robert J. Marshall Jr. | Chief Financial Officer & Treasurer | USD 991,665 | Male | 1966 | Active |
Daniel Niedzwiecki | Chief Administrative Officer, General Counsel & Corporate Secretary | USD 763,085 | Male | 1977 | Active |
Amanda Morgan | Chief Commercial Officer | USD 677,449 | Female | 1979 | Active |
Mary Anne Heino | CEO & Executive Chairperson | USD 673,968 | Female | 1960 | Active |
Mark Richard Kinarney | Vice President of Investor Relations | — | Male | — | Active |
Dorothy Barr | Senior Vice President of Manufacturing & Technical Operations | — | Female | — | Active |
Neil Holland | Vice President of Business Insights & Operations | — | Male | — | Active |
Kimberly Brown | Chief Accounting Officer | — | Female | 1990 | Active |
Linda S. Lennox | Vice President of Corporate Communications & Chief of Staff | — | Female | 1965 | Active |
Lee Anne Howe | Chief Information Officer | — | Female | — | Active |
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Lantheus Holdings, Inc. (NASDAQ: LNTH) PR Newswire
NEW YORK, Aug. 3, 2026 /PRNewswire/ -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2025 ISS Securities Class Action Services Report. The firm is headquartered at the Empire State Building in New York City and is investigating Lantheus Holdings, Inc. (NASDAQ: LNTH ) related to its sale to Curium US Holdings LLC.
Are SUPN, ITGR, ATKR, LNTH Obtaining Fair Deals for their Shareholders? PR Newswire NEW YORK, Aug. 3, 2026
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws
Shareholder Alert: Ademi LLP investigates whether Lantheus Holdings, Inc. is obtaining a Fair Price for Public Shareholders PR Ne
